The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd

BSE 536565 · NSE NOVELIX · ISIN INE314I01036 · Group XT · Active

Healthcare › Healthcare › Healthcare Services › Healthcare Research, Analytics & Technology

₹80.50

-0.43%

BSE close, 28 August 2026

Market cap

₹192.35 cr

2.4 cr shares · Micro cap

Free float

₹43.61 cr

as published

P/E · P/B

63.4× · 25.56×

EPS ₹1.27 · BV ₹3.15

FY25-26 rev / PAT

132.31 / 2.56

₹ cr, as filed

Filings, window

17

4 selected · 24%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹38.00 52-WK HIGH ₹92.00 ₹80.50 79% of range
Against 52-week high-12.5%
Against 52-week low+111.8%
Day change-0.43%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹1.27
Price / earnings63.39×
Price / book25.56×
Book value — derived, price ÷ P/B₹3.15
Return on equity40.40%
Operating margin3.52%
Net margin3.19%

Consistency check

P/B ÷ P/E, which must equal ROE
40.32%
ROE as published
40.40%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 36.91 1.18 0.49 3.52% 3.19%
Mar-26 · Q 25.19 0.91 0.43 5.08% 3.62%
FY25-26 132.31 2.56 1.21 2.65% 1.93%

Quarter on quarter

Revenue, quarter on quarter
+46.5%
Net profit, quarter on quarter
+29.7%
Operating margin, quarter on quarter
-156 bps

Disclosure profile 17 filings in the window

0 median 17.0 p75 · 25 sector max 52 17 51th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Change in Directorate2
Board Outcome1
Results1
Selected sub-total4
Procedural
AGM / EGM5
General2
Annual Report1
Board Meeting1
Compliance Certificate1
Newspaper Publication1
Other Update1
Trading Window1
Procedural sub-total13
Total17

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group XT, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

17 filings · 4 selected · busiest 2026-08-13 and 2026-09-07

Filing rhythm · the twelve most recent

2026-08-312026-10-06

SelectedProcedural

Filings

17 in the window · 25 earlier on record

  1. 6 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Submission of Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018.

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 2 October 2026 ·

    Change in Directorate

    Change in Directorate

    Attached

    Company Update / Change in Directorate View filing →

  3. 1 October 2026 ·

    AGM / EGM

    Shareholders Meeting- Voting Results

    Attached

    AGM/EGM / AGM View filing →

  4. 1 October 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of Voting results & Scrutinizers Report.

    AGM/EGM / AGM View filing →

  5. 30 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Submission of Outcome of the 32nd Annual General Meeting.

    AGM/EGM / AGM View filing →

  6. 30 September 2026 ·

    Trading Window

    Closure of Trading Window

    Attached

    Insider Trading / SAST / Closure of Trading Window View filing →

  7. 9 September 2026 ·

    Newspaper Publication

    Newspaper Publication

    Submission of Newspaper Publication.

    Company Update / Newspaper Publication View filing →

  8. 7 September 2026 ·

    General

    Letter Of Annual Report & AGM Notice Weblink

    Attached.

    Company Update / General View filing →

  9. 7 September 2026 ·

    AGM / EGM

    Shareholders Meeting- Notice Of Annual General Meeting To Be Held On Wednesday, 30Th September, 2026.

    Attached.

    AGM/EGM / AGM View filing →

  10. 7 September 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Submission of annual report for the financial year ended March 31, 2026.

    Others / Reg. 34 (1) Annual Report View filing →

  11. 31 August 2026 ·

    AGM / EGM

    Shareholders Meeting AGM On 30Th September, 2026.

    Submission of Intimation of AGM Date.

    AGM/EGM / AGM View filing →

  12. 31 August 2026 ·

    Change in Directorate

    Change in Directorate

    Submission of intimation of change in Designation of Director.

    Company Update / Change in Directorate View filing →

  13. 25 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Saturday, 29Th August, 2026

    Novelix Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2026 ,inter alia, to consider and approve Submission of Prior ....

    Board Meeting / Board Meeting View filing →

  14. 20 August 2026 ·

    General

    Lease Deed

    Submission of Intimation of Land Lease Deed.

    Company Update / General View filing →

  15. 13 August 2026 ·

    Other Update

    Compliances- Statement Of Deviation & Variation

    Submission of Statement of Deviation & Variation

    Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →

  16. 13 August 2026 ·

    Results

    Results- Financial Results For June 30, 2026.

    Submission of financial Results for the quarter ended 30th June, 2026.

    Result / Financial Results View filing →

  17. 13 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, 13Th August, 2026 Pursuant To Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

    Submission of outcome of the Board meeting.

    Board Meeting / Outcome of Board Meeting View filing →

RSS feed for Novelix Pharmaceuticals Ltd · the 50 most recent filings